

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 March 2023 (09.03.2023)



(10) International Publication Number
WO 2023/034923 A3

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 14/71 (2006.01)
A61P 35/00 (2006.01) C07K 14/28 (2006.01)
C07K 14/495 (2006.01)

(21) International Application Number:

PCT/US2022/075847

(22) International Filing Date:

01 September 2022 (01.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/240,404 03 September 2021 (03.09.2021) US

(71) Applicant: NOVAROCK BIOTHERAPEUTICS, LTD.

[US/US]; 801 Charles Ewing Blvd., Ewing, New Jersey 08628 (US).

(72) Inventors: PEI, Yi; 1836 Glenwold Drive, Paoli, New

Jersey 19301 (US). HUANG, Haichun; 4329 Crestwood Street, Fremont, California 94538 (US). LOI, Yick; 23 Windsor Drive, East Brunswick, New Jersey 08816 (US). CHEN, Chang Hung; 13623 Palmetto Circle, Germantown, Maryland 20874 (US). LI, Han; 1 Claire Dr., Newtown, Pennsylvania 18940 (US). SHEN, Di; 119 Bedford Ct, Piscataway, New Jersey 08854 (US). LEI, Ming; 20 Lockwood Drive, Princeton, New Jersey 08540 (US).

(74) Agent: MORGAN, LEWIS & BOCKIUS LLP; 110 North Wacker Drive, Suite 2800, Chicago, Illinois 60606 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGF β AND USES THEREOF




FIG. 13A

(57) Abstract: The disclosure provides binding proteins that bind PD-L1 and CD137 (PD-L1/CD137 bispecific), binding proteins that bind PD-L1 and TGF β (PD-L1/TGF β bispecific), binding proteins that bind PD-L1, TGF β , and CD137 (PD-L1/TGF β /CD137 trispecific), and binding proteins that bind CD137, TGF β , and PD-L1 (CD137/TGF β /PD-L1 trispecific). The disclosure also provides pharmaceutical compositions comprising these binding proteins, and methods of their use to treat and/or prevent cancer.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

15 June 2023 (15.06.2023)

(15) Information about Correction:

see Notice of 11 May 2023 (11.05.2023)